Nuvaxovid the 5th COVID-19 vaccine approved in the EU. [EPA-EFE/JEROEN JUMELET]
The EU-approved COVID-19 vaccine, Nuvaxovid, will not be given to others under the age of 30 due to the increased health risks it poses, Sweden’s Public Health Agency announced this week.
Nuvaxovid the 5th COVID-19 vaccine approved through the EU.
After first approving the vaccine for others over the age of 18, the Public Health Agency announced Tuesday that the vaccine poses a risk to others under 30 because it increases the risk of central muscle inflammation and pericarditis, more commonly known as inflammation. Central muscle and pericardial effusion: the threat remains “very low”.
“We are closely monitoring the scenario and waiting for more data. But anyone who is younger and has recently been vaccinated with Nuvaxovid need not worry. The threat is very low and you can continue with the next dose with some other vaccine. “Sören Andersson, head of the vaccination program unit, in a message on the fitness agency’s website.
The firm said the vaccine has still been widely used in Sweden, with the total number of doses administered reaching about 7,000.
Sweden has in the past suspended the management of other COVID-19 vaccines.
While it has to administer Moderna’s Spikevax vaccine only to other people born after 1991, it has Array for now, to absolutely prevent AstraZeneca, although the European Medicines Agency (EMA) advised reinstating the vaccine for others over 65 since then. Effects such as blood clots combined with low platelet counts or bleeding have only been seen in people younger than 65.
Since early 2022, the company has advised that the Moderna vaccine not be used in other people under the age of 30. For others in this age group, the Pfizer vaccine suggests.
Sweden’s announcement came at a time when the European Commission has been silent on how it bought the COVID-19 vaccine against the pandemic, while questioning alleged links between Commission President Ursula von der Leyen and Pfizer’s chief executive.
On October 14, the European Public Prosecutor’s Office announced the opening of an investigation into the acquisition of vaccines through the European Commission in the face of the pandemic.
(Charles Szumski | EURACTIV. com)